purpose to preliminarily evaluate the clinical efcacy andsafety of drug-eluting bead transarterial chemoembolization (deb-tace) for unresectable soft tissue sarcoma refractory to systemic chemotherapy.
methods tenpatients with refractory sarcoma who underwent deb-tace therapybetween january2015 and january 2017 were identifed. clinical information and radiological data were retrospectively collected to analyze tumor response,overall survival(os), progression-free survival and adverse events (aes). tumor response to deb-tace was assessed with modifed response evaluation criteria in solid tumors(mrecist) guidelines applied to computed tomography or magnetic resonance imaging.
results all deb-tace procedures were successfully performed for ten patients with 15 tumor lesions. the median follow-up duration was 19 months and the median survival time was 21 months (range 11–30 months). the 1- and 2-year os rate was 90 and30%, respectively.according to the guidance of mrecist, complete response,partial response,stable disease and progressive disease were noted in zero(0%), three (30%),four (40%) and three (30%) patients, respectively. the disease control rate and objective responserate was 70 and 30%, respectively. there were no seriousaes in patients afterdeb-tace.
conclusions our data showed that deb-tace was efective and safe for patients with soft tissue sarcoma. therefore,deb-tace can be considered as an alternative treatment option for unresectable soft tissue sarcoma refractory to conventionally systemic chemotherapy.